Cost-minimization analysis of HYQVIA® in the treatment of primary immunodeficiency disease (PID) and secondary immunodeficiency disease (SID) in Italy

Background: Primary (PID) or secondary (SID) immunodeficiencies are diseases caused by quantitative and/or functional alterations of the different mechanisms involved in innate and adaptive immune response. This economic evaluation was conducted to compare cost treatment HYQVIA® (hyaluronidase-facilitated subcutaneous infusion immunoglobulin, fSCIG) compared intravenous immunoglobulin (IVIG) (SCIG), currently reimbursed Italy, PIDs SIDs. Methods: A cost-minimisation analysis carried out, considering hospital’s perspective. The direct medical costs (cost immunoglobulins administration) were assessed. one year (52 weeks) time horizon. reference population included adult patients with PID impaired antibody production SID severe recurrent infections, ineffective antimicrobial documented specific defect (PSAF) serum IgG level < 4 g/L. Results: In maintenance PID, (€ 20,020.00) therapeutic alternative lowest mean annual HIZENTRA® 22,165.19) VENITAL® 24,967.68). Moreover, SIDs, 17,160.00) cost-saving 22,107.68). sensitivity confirmed base case results. Conclusion: Due lower administration scheme administration, a SCIG e IVIG